Expression vectors containing isolated nucleic acids encoding anti-human IL-6 antibody
View Patent ↗The invention relates to anti-human interleukin 6 antibodies and antibody fragments, nucleic acids and vectors which encode for these antibodies and antibody fragments the use thereof in therapy and diagnosis.
1. A vector containing an isolated nucleic acid that encodes for an anti-human interleukin-6 (“IL-6”) antibody or antigen-binding fragment wherein the anti-human IL-6 antibody or antibody fragment comprises: a variable light (V L ) region comprising complementarity region CDR1, CDR2 and CDR3 polypeptides, respectively having the sequences of SEQ ID NO:4, 5 and 6, and a variable heavy (V H ) region comprising complementarity region CDR1, CDR2 and CDR3 polypeptides, respectively having the sequences of SEQ ID NO:7, 8 or 120 and 9.
2. The vector of claim 1 , wherein the V L region comprises CDR1, CDR2 and CDR3 polypeptides, respectively having the sequences of SEQ ID NO:4, 5 and 6, and the V H region comprises CDR1, CDR2 and CDR3 polypeptides, respectively having the sequences of SEQ ID NO:7, 120 and 9.
3. The vector of claim 1 , wherein the V L region comprises CDR1, CDR2 and CDR3 polypeptides, respectively having the sequences of SEQ ID NO:4, 5 and 6, and the V H region comprises CDR1, CDR2 and CDR3 polypeptides, respectively having the sequences of SEQ ID NO:7, 8 and 9.
4. The vector of claim 1 , wherein the variable light chain comprises a polypeptide which is at least 90% identical to a polypeptide having the sequence of SEQ ID NO:20 and further comprising the CDR1, CDR2 and CDR3 polypeptides of SEQ ID NO:4, 5 and 6.
5. The vector of claim 1 , wherein the variable heavy chain comprises a polypeptide which is at least 90% identical to the to a polypeptide having the sequence of SEQ ID NO: 18 or 19 and further comprising the CDR1, CDR2 and CDR3 polypeptides of SEQ ID NO: 7, 120 and 9.
6. The vector of claim 1 , wherein the variable heavy chain comprises a polypeptide which is at least 90% identical to a polypeptide having the sequence of SEQ ID NO: 18 or 19 and further comprising the CDR1, CDR2 and CDR3 polypeptides of SEQ ID NO: 7, 8 and 9.
7. The vector of claim 1 , wherein the variable light chain comprises a polypeptide which is at least 90% identical to the light chain framework region having the sequence of SEQ ID NO:20 and further comprising the CDR1, CDR2 and CDR3 polypeptides of SEQ ID NO:4, 5 and 6 and the variable heavy chain comprises a polypeptide which is at least 90% identical to the heavy chain framework region having the sequence of SEQ ID NO:18 or 19 and further comprising the CDR1, CDR2 and CDR3 polypeptides of SEQ ID NO:7, 120 and 9.
8. The vector of claim 1 , wherein the variable light chain comprises a polypeptide which is at least 90% identical to the light chain framework region having the sequence of SEQ ID NO:20 and further comprising the CDR1, CDR2 and CDR3 polypeptides of SEQ ID NO:4, 5 and 6 and the variable heavy chain comprises a polypeptide which is at least 90% identical to the heavy chain framework region having the sequence of SEQ ID NO:18 or 19 and further comprising the CDR1, CDR2 and CDR3 polypeptides of SEQ ID NO:7, 8 and 9.
9. The vector of claim 1 , wherein the variable light chain comprises a polypeptide which is at least 95% identical to a polypeptide having the sequence of SEQ ID NO:20 and further comprising the CDR1, CDR2 and CDR3 polypeptides of SEQ ID NO:4, 5 and 6.
10. The vector of claim 1 , wherein the variable heavy chain comprises a polypeptide which is at least 95% identical to a polypeptide having the sequence of SEQ ID NO: 18 or 19 and further comprising the CDR1, CDR2 and CDR3 polypeptides of SEQ ID NO: 7, 120 and 9.
11. The vector of claim 1 , wherein the variable heavy chain comprises a polypeptide which is at least 95% identical to a polypeptide having the sequence of SEQ ID NO: 18 or 19 and further comprising the CDR1, CDR2 and CDR3 polypeptides of SEQ ID NO: 7, 8 and 9.
12. The vector of claim 1 , wherein the variable light chain comprises a polypeptide which is at least 95% identical to the light chain framework region having the sequence of SEQ ID NO:20 and further comprising the CDR1, CDR2 and CDR3 polypeptides of SEQ ID NO:4, 5 and 6 and the variable heavy chain comprises a polypeptide which is at least 95% identical to the heavy chain framework region having the sequence of SEQ ID NO:18 or 19 and further comprising the CDR1, CDR2 and CDR3 polypeptides of SEQ ID NO:7, 120 and 9.
13. The vector of claim 1 , wherein the variable light chain comprises a polypeptide which is at least 95% identical to the light chain framework region having the sequence of SEQ ID NO:20 and further comprising the CDR1, CDR2 and CDR3 polypeptides of SEQ ID NO:4, 5 and 6 and the variable heavy chain comprises a polypeptide which is at least 95% identical to the heavy chain framework region having the sequence of SEQ ID NO:18 or 19 and further comprising the CDR1, CDR2 and CDR3 polypeptides of SEQ ID NO:7, 8 and 9.
14. The vector of claim 1 , wherein the variable heavy chain comprises a polypeptide which is at least 98% identical to a polypeptide having the sequence of SEQ ID NO: 18 or 19 and further comprising the CDR1, CDR2 and CDR3 polypeptides of SEQ ID NO: 7, 120 and 9.
15. The vector of claim 1 , wherein the variable heavy chain comprises a polypeptide which is at least 98% identical to a polypeptide having the sequence of SEQ ID NO: 18 or 19 and further comprising the CDR1, CDR2 and CDR3 polypeptides of SEQ ID NO: 7, 8 and 9.
16. The vector of claim 1 , wherein the variable light chain comprises a polypeptide which is at least 98% identical to the light chain framework region having the sequence of SEQ ID NO:20 and further comprising the CDR1, CDR2 and CDR3 polypeptides of SEQ ID NO:4, 5 and 6 and the variable heavy chain comprises a polypeptide which is at least 98% identical to the heavy chain framework region having the sequence of SEQ ID NO:18 or 19 and further comprising the CDR1, CDR2 and CDR3 polypeptides of SEQ ID NO:7, 120 and 9.
17. The vector of claim 1 , wherein the variable light chain comprises a polypeptide which is at least 98% identical to the light chain framework region having the sequence of SEQ ID NO:20 and further comprising the CDR1, CDR2 and CDR3 polypeptides of SEQ ID NO:4, 5 and 6 and the variable heavy chain comprises a polypeptide which is at least 98% identical to the heavy chain framework region having the sequence of SEQ ID NO:18 or 19 and further comprising the CDR1, CDR2 and CDR3 polypeptides of SEQ ID NO:7, 8 and 9.
18. The vector of claim 1 , wherein the variable heavy chain comprises a polypeptide which is identical to the to a polypeptide having the sequence of SEQ ID NO: 18 or 19 and further comprising the CDR1, CDR2 and CDR3 polypeptides of SEQ ID NO: 7, 120 and 9.
19. The vector of claim 1 , wherein the variable heavy chain comprises a polypeptide which is identical to the to a polypeptide having the sequence of SEQ ID NO: 19 and further comprising the CDR1, CDR2 and CDR3 polypeptides of SEQ ID NO: 7, 8 and 9.
20. The vector of claim 1 , wherein the variable heavy chain comprises a polypeptide which is identical to a polypeptide having the sequence of SEQ ID NO: 18 and further comprising the CDR1, CDR2 and CDR3 polypeptides of SEQ ID NO: 7, 8 and 9.
21. The vector of claim 1 , wherein the variable light chain comprises a polypeptide which is identical to the light chain framework region having the sequence of SEQ ID NO:20 and further comprising the CDR1, CDR2 and CDR3 polypeptides of SEQ ID NO:4, 5 and 6 and the variable heavy chain comprises a polypeptide which is identical to the heavy chain framework region having the sequence of SEQ ID NO:19 and further comprising the CDR1, CDR2 and CDR3 polypeptides of SEQ ID NO:7, 120 and 9.
22. The vector of claim 1 , wherein the variable light chain comprises a polypeptide which is identical to the light chain framework region having the sequence of SEQ ID NO:20 and further comprising the CDR1, CDR2 and CDR3 polypeptides of SEQ ID NO:4, 5 and 6 and the variable heavy chain comprises a polypeptide which is identical to the heavy chain framework region having the sequence of SEQ ID NO:18 and further comprising the CDR1, CDR2 and CDR3 polypeptides of SEQ ID NO:7, 8 and 9.
23. The vector of claim 1 , wherein said encoded anti-human IL-6 antibody or fragment is a human, humanized or chimeric anti-human IL-6 antibody or fragment thereof.
24. The vector of claim 1 , wherein said encoded anti-human IL-6 antibody or fragment contains a human Fc region.
25. The vector of claim 24 wherein said Fc region is of the IgG1, IgG2, IgG3 or IgG4 isotype.
26. The vector of claim 24 wherein said Fc region is of the IgG1 isotype.
27. The vector of claim 1 , wherein said encoded anti-human IL-6 antibody or fragment contains an Fc region that has been modified to alter effector function, half-life, proteolysis, and/or glycosylation.
28. The vector of claim 1 , wherein said anti-human IL-6 antibody or fragment binds to IL-6 with a dissociation constant (K D ) of less than or equal to 5×10 −7 , 10 −7 , 5×10 −8 , 5×10 −9 , 10 −9 , 5×10 −10 , 10 −10 , 5×10 −11 , 10 −11 , 5×10 −12 , 10 − , 5 × 10 −13 , or 10 −13 .
29. The vector of claim 1 , wherein said anti-human IL-6 antibody or fragment binds to IL-6 with a dissociation constant (K D ) of less than or equal to 5×10 −11 .
30. The vector of claim 1 , wherein said anti-human IL-6 antibody or fragment is a humanized antibody or antibody fragment.
31. A host cell containing the vector of claim 1 .
32. The host cell of claim 31 which is a mammalian or yeast cell.
33. The host cell of claim 32 , wherein said yeast cell is Pichia pastoris.
34. The host cell of claim 32 , wherein said mammalian cell is a Chinese hamster ovary (“CHO”) cell.